Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OXNAD1 encodes a mitochondrial protein with a predicted NAD-binding oxidoreductase domain, implicated broadly in cellular redox reactions and metabolism. While its specific physiological function in humans is not well defined, it is classified bioinformatically as an oxidoreductase based on conserved catalytic domain architecture. The protein is likely involved in metabolite interconversion and redox balance in mitochondria but lacks detailed functional annotation from direct experimental studies. There are nominal disease associations (phototoxic dermatitis, basal cell nevus syndrome 1) derived from gene-disease association databases, but no clear mechanistic or therapeutic links have been established. OXNAD1 is not an established drug target, and there is no evidence to support its use as a biomarker or as a source of safety concerns in therapeutic settings.
Not applicable; OXNAD1 is not a confirmed drug target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oxidoreductase NAD-binding domain-containing protein 1 (OXNAD1).